Showing 3581-3590 of 8791 results for "".
Take 5: Clinically-Relevant Findings About Causes and Treatment of Rosacea
https://practicaldermatology.com/columns/take-5/take-5-clinically-relevant-findings-about-causes-and-treatment-of-rosacea/21870/Research sheds light on the pathogenesis of the disease and patients' experience.Therapeutics Update: Product News
https://practicaldermatology.com/topics/general-topics/therapeutics-update-product-news/21894/Take 5: New Developments in the Realm of STIs and STDs
https://practicaldermatology.com/columns/take-5/take-5-new-developments-in-the-realm-of-stis-and-stds/21969/New data and recent advancements highlight the importance of education and prevention.Take 5: Recent Developments in Systemic Therapy for Psoriasis
https://practicaldermatology.com/columns/recent-developments/take-5-recent-developments-in-systemic-therapy-for-psoriasis/22002/New data reveal noteworthy financial and clinical trends in the use of systemic agents.Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Lead from Ahead (For a Change)
https://practicaldermatology.com/topics/practice-management/lead-from-ahead-for-a-change/23973/Access Is Everything
https://practicaldermatology.com/topics/practice-management/access-is-everything/23942/The Safe Step Act of 2023 seeks to rein in fail-first policies and protect patients.Letter to the Editor
https://practicaldermatology.com/columns/letter-to-the-editor/letter-to-the-editor-3/23917/Lose Your Inhibitions: Expanding Use of JAK Inhibitors
https://practicaldermatology.com/topics/atopic-dermatitis/lose-your-inhibitions-expanding-use-of-jak-inhibitors/23910/Despite data on safety concerns, dermatologists and patients see benefits.